RxDoctor Payments Data

Daniel Nguyen, MD

Clinical Cardiac Electrophysiology · Orlando, FLNPI 1467794560

Payments from drug & device makers

$47,296in general payments, 2019–2025

Across 255 payments — averaging $185.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$19K
  • Boston Scientific$14K
  • Abbott$8K
  • Altathera Pharmaceuticals LLC$2K
  • Biotronik Inc.$2K
  • Biosense Webster, Inc.$918
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$1,8754%
  • Grants$31,21266%
  • Travel & lodging$4,1859%
  • Food & beverage$9,38120%
  • Education$6431%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,296 in reported general payments places this provider in the 55th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$285,769
Medicare patients
908
Services billed
3,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban253$292,474
XareltoRivaroxaban63$79,220
EntrestoSacubitril/Valsartan11$20,106
MultaqDronedarone Hcl17$18,668
Dofetilide44$10,016
Amiodarone Hcl151$4,204
Metoprolol Succinate155$2,599
Mexiletine Hcl18$2,282
Flecainide Acetate29$1,507
SotalolSotalol Hcl55$1,362
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$1,124
Bisoprolol Fumarate21$826
Metoprolol Tartrate64$576
Carvedilol48$509
ClopidogrelClopidogrel Bisulfate32$421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$292,474253 claims
Johnson & JohnsonXarelto$117$79,22063 claims
NovartisEntresto$135$20,10611 claims
Sanofi-aventis U.S. LLCMultaq$56$18,66817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →